Published in Medical Letter on the CDC and FDA, March 12th, 2006
The company has selected the principal investigator for its Australian phase II metastatic renal cell carcinoma trial and begun identifying suitable trial sites. The manufacturing and quality agreements for the good manufacturing practices (GMP) production of the clinical trial material are now in place with Patheon U.K. Limited. It is expected that the Australian trials will commence recruitment during Q2 2006.
Solbec is also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA